• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Nutraceuticals for Men: Muscle Health and Performance Nutrition

    Aging in Place: Healthy Lifestyles Supplement Science-Based Solutions

    Getting an Edge in Esports: Meeting the Health Needs of Competitive Gamers

    Beyond CBD: Cannabis Compounds Warrant Recognition and More Research

    Leveling Out the Energy Segment for Mainstream, and Rethinking Caffeine
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan

    Solvay Invests in Suanfarma’s Vanillin Production

    GNC Adds Products from The Honest Company, Hers, and Womaness

    NSF and SCNM’s School of Nutrition Collaborate on Master of Science Program

    Walgreen’s Brand Vitamins and Supplements First to Carry UL Verified Mark
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan

    Solvay Invests in Suanfarma’s Vanillin Production

    Tocotrienols May Aid Weight Loss and Cognitive Performance, Animal Study Finds

    Leaven Essential to Launch Branded Botanical Extracts to Global Markets

    How Will China’s Immunity Gap Impact the Dietary Ingredients Supply Chain?
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan

    Experts Debate Role of Supplements in Improving Public Health in EU

    Solvay Invests in Suanfarma’s Vanillin Production

    GNC Adds Products from The Honest Company, Hers, and Womaness

    Walgreen’s Brand Vitamins and Supplements First to Carry UL Verified Mark
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Experts Debate Role of Supplements in Improving Public Health in EU

    GNC Adds Products from The Honest Company, Hers, and Womaness

    Tocotrienols May Aid Weight Loss and Cognitive Performance, Animal Study Finds

    Red Seaweed Digestive Supplement for Cattle Could Reduce Enteric Methane Emissions by 80%

    Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Sabinsa Corporation

    ESHA Research

    Applied Food Sciences, Inc.

    Botanic Healthcare LLC

    Atlantia Clinical Trials
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Sabinsa Corporation

    ESHA Research

    Applied Food Sciences, Inc.

    Botanic Healthcare LLC

    Atlantia Clinical Trials
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Understanding Exclusion (Preclusion) and a Proposed Solution

    Confusion regarding interpretation of language in the Food, Drug, and Cosmetic Act requires some clarification.

    Understanding Exclusion (Preclusion) and a Proposed Solution
    Related CONTENT
    • Experts Debate Role of Supplements in Improving Public Health in EU
    • Quality Testing of CoQ10 and Quercetin Brands Sold on Amazon Finds Continued Failure
    • Red Seaweed Digestive Supplement for Cattle Could Reduce Enteric Methane Emissions by 80%
    • Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults
    • Nexira to Discuss Four New Scientific Studies at Vitafoods Europe
    By Todd Harrison, Venable11.11.21
    Under the Federal Food, Drug, and Cosmetic Act (FDCA), drugs are defined as products intended for use in the diagnosis, treatment, or prevention of disease,1 and are subject to extensive premarket approval requirements.2 These requirements focus on the unique formulation of a drug, its active moiety, and its routes of administration to evaluate the drug’s safety and efficacy.

    By comparison, dietary supplements are considered a subset of food3 that are ingested and intended to support or maintain health via one or more “dietary ingredients.”4 Similarly, medical foods are also considered foods with their own unique provisions. Finally, functional foods are merely conventional foods and are regulated in a similar manner.

    Neither foods—including medical foods—nor dietary supplements are subject to premarket approval requirements like drugs. The only exception to this rule are “food additives,” which are subject to their own exception for ingredients that are generally recognized as safe (GRAS) for use in human food.

    There remains a misconception that the New Dietary Ingredient Notification process is an approval process, when in fact it is merely a notification process, as the title indicates. Indeed, a review of FDA’s negative courtesy letters on new dietary ingredients—yes, these are merely courtesy letters—shows the agency is very careful never to state an ingredient “is” adulterated, but rather “may be” adulterated under the Act.

    Essentially FDA is saying: “we understand that this is a notification, so don’t believe this letter affords you any right to sue us if you don’t like the comments in the letter.”

    Similarly, a positive response should be viewed as follows: “have a nice life, but if something goes wrong we have plausible deniability.” In the end, once the NDIN is filed then you are free to market after 75 days, at your own risk of potential regulatory action.

    Two Exclusions
    With that said, there are two provisions in the FDCA that do affect the ability of a company to market a particular ingredient as either a dietary ingredient or a food ingredient. As this has most often come up in the dietary supplement context, recently with CBD, NAC, and vinpocetine, I will primarily address the preclusion issue for dietary ingredients while touching on 301(ll).

    Specifically, the FDCA provides that a product cannot be marketed as a dietary supplement if it includes an “article” that has been: (1) approved as a new drug; or (2) authorized for investigation as a new drug (a) for which substantial clinical investigations have been instituted on the article and their existence made public, and (b) was not marketed as a food or dietary supplement prior to being authorized for investigation as a new drug.5

    As a practical matter, both exclusions hinge on whether the ingredient was first marketed as a food or dietary supplement prior to approval or investigation as a new drug. For those ingredients that are not approved but are subject only to investigation prior to use in a dietary supplement, a determination must be made whether the ingredient has been authorized for investigation as a new drug and has been subject to “substantial clinical investigation.”

    On the first point, the statute would seem relatively straightforward in establishing that an ingredient can properly be considered a dietary ingredient for use as or in a dietary supplement so long as the ingredient was first marketed as a food or dietary supplement before becoming the subject of a drug investigation. Unfortunately, it is not so straightforward. 

    More specifically, FDA’s interpretation of this provision is extremely restrictive to mean that as long as the active moiety was either approved or underwent substantial clinical investigation, regardless of dose or route of administration, the ingredient is precluded. This makes little sense from a scientific perspective, as it is quite possible that 10 mg of an ingredient will act very differently than 500 mg. Moreover, whether an ingredient is administered through digestion, inhalation, or injection may very well impact the safety and efficacy of the ingredient.  

    I would further note, Congress specifically used the term “article,” which encompasses more than just the active moiety, but the full formulation. Thus, Congress should consider amending this part of the statute to specifically state that the article means not simply the presence of the active moiety, but also dosage and route of administration. Alternatively, it could borrow from the medical device language and use the term “substantially equivalent” with the burden on the company to show its proposed use is not “substantially equivalent” to the article of the drug while requiring any decision by FDA to the contrary be subject to judicial review—thus holding feet to the fire for both the company in the first instance and FDA in the second.  

    What’s ‘Substantial’?
    Another problematic scenario, if the ingredient is not an FDA-approved drug but has been subject to clinical trials, relates to determining whether those trials are substantial or not.

    The legislative history behind the Dietary Supplement Health and Education Act (DSHEA) is equally thin, merely noting that “substantial clinical investigations” do not include a special type of investigational new drug (IND) referred to as “compassionate use” or single-patient studies.6

    The agency has never attempted to define the limits of this provision. With that said, the FDA in 2008 did request comments to § 301(ll), which is the exclusionary language related to food ingredients that had undergone substantial clinical trials.7 Specifically, the FDA requested comments related to “substantial clinical investigations” that have been instituted, as well as its applicability to dietary ingredients as a subgroup of foods.8

    Importantly, however, FDA has never discussed the comments received nor attempted to define the term “substantial clinical investigations,” or attempt to argue that § 301(ll) applies to dietary supplements. Thus, the FDA’s reluctance to impose its own definition of “substantial clinical investigations” provides a window into its thought process, as it has only raised the issue when it believes significant Phase II and III trials have been conducted. Thus, it is unclear  whether limited Phase I and Phase IIA trials are considered substantial if the drug pathway was abandoned shortly thereafter and the abandonment was unrelated to the safety of the ingredient.

    I would further note there is an important distinction between the exclusion language for food and food ingredients under § 301(ll) and its sister provision for dietary supplements under § 201(ff)(3). Under § 201(ff), “substantial clinical investigation” is directly tied to an “authorized” investigation for a new drug. This means that ingredients which are first used under an authorized IND and undergo substantial clinical trials cannot be used as or in a dietary supplement. By comparison, § 301(ll) does not feature the IND component found in § 201(ff).  Instead, the statute as worded only encompasses the institution of “substantial clinical trials,” which could be interpreted to mean any phase of a clinical trial. 

    Regardless, the absence of an IND is an important aspect to determine whether an ingredient may be excluded as a dietary ingredient but not a food ingredient. To state it differently, an ingredient that is not the subject of an IND but still subject to substantial clinical trials may nevertheless be marketed as a dietary supplement even though it may be excluded as a food ingredient.

    Further, any attempt to apply the general food exclusionary provision to dietary supplements would be improper under basic constructs of statutory interpretation, which dictate specific statutory controls over language found in a more general provision. Taken together, there is an added layer of interpretation when attempting to define whether an ingredient has been subject to a sufficient degree of drug evaluation to be considered “substantial.”

    Because of the differences in the statutory language between 201(ff)(3) and 301(ll), I would propose amending these two provisions into one new section that applies to both food and dietary supplements while also stating that “substantial” investigation relates to initiation of clinical trials that have not been abandoned for safety reasons prior to the initiation of Phase III clinical trials. 

    Legislative Proposal
    In the hope of fostering dialogue, I am proposing the following legislative language: 

    An Article that is approved as a new drug under section 355 of this title or licensed as a biologic under section 262 of title 42 and was, prior to such approval, certification, or license, marketed as a food or dietary ingredient unless the Secretary has issued a regulation, after notice and comment, finding that the article, when used as or in a dietary supplement under the conditions of use and dosages set forth in the labeling for such dietary supplement, is unlawful under section 342(f) of this title; and not include—

    (i) a food or dietary ingredient that is substantially equivalent that was not marketed prior to an approved new drug under section 355 of this title, certified as an antibiotic under section 357 of this title, or licensed as a biologic under section 262 of title 42, or

    (ii) a food or dietary ingredient that is substantially equivalent and was not marketed prior to the filing of an Investigational New Drug Application as a new drug, antibiotic, or biological for which Phase III clinical investigations have been authorized and Phase I or II clinical investigations have not been otherwise abandoned for safety reasons and for which the existence of such investigations has been made public, which was not before such approval, certification, licensing, or authorization marketed as a dietary supplement or as a food unless the Secretary, in the Secretary’s discretion, has issued a regulation, after notice and comment, finding that the article would be lawful under this chapter. For purposes of this paragraph, the applicable date is the date of enrollment into Phase I or II clinical investigations that eventually led to the initiation of Phase III clinical investigation.  

    For purpose of this section, substantial equivalence shall mean that the food or dietary ingredient exhibits the same pharmacological effect as the active moiety in the finished drug product, the following factors must be taken into consideration by the Secretary in making this determination must not only consider the pharmacological effect but the route of administration and dosage level.  

    Judicial Review — The decision of the Secretary to find that either a food or dietary ingredient is precluded is subject to immediate judicial review with the Agency having the burden to establish that the ingredient is “substantially” equivalent to an article approved as a drug. 

    References
    1. 21 U.S.C. § 201(g)(1)
    2. See, e.g., 21 U.S.C. § 355 et seq.
    3. 21 U.S.C. § 201(ff).
    4. Id. § 201(ff)(1).
    5. Id. § 201(ff)(3)(B)(ii). For purposes of this exclusion, FDA has interpreted “authorized for investigation as a new drug” to mean that an investigational new drug application (“IND”) has been submitted and taken effect. See FDA, Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues (Oct. 2016).
    6. Dietary Supplement Health & Education Act, Pub. L. No. 103–417, 108 Stat. 4325 (1994).
    7. 73 Fed. Reg. 43937, 43939 (July 29, 2008).
    8. Id.


    About the Author: Todd Harrison is partner with Venable, which is located in Washington, D.C. He advises food and drug companies on a variety of FDA and FTC matters, with an emphasis on dietary supplement, functional food, biotech, legislative, adulteration, labeling and advertising issues. He can be reached at 575 7th St. NW, Washington, D.C. 20004, Tel: 202-344-4724; E-mail: taharrison@venable.com.
    Related Searches
    • Delivery & Dosage Technologies
    • Quality & Safety
    • Dietary Supplements
    • Regulations
    Related Knowledge Center
    • Quality & Safety
    • Delivery & Dosage Technologies
    • Dietary Supplements
    Suggested For You
    Experts Debate Role of Supplements in Improving Public Health in EU Experts Debate Role of Supplements in Improving Public Health in EU
    Quality Testing of CoQ10 and Quercetin Brands Sold on Amazon Finds Continued Failure Quality Testing of CoQ10 and Quercetin Brands Sold on Amazon Finds Continued Failure
    Red Seaweed Digestive Supplement for Cattle Could Reduce Enteric Methane Emissions by 80% Red Seaweed Digestive Supplement for Cattle Could Reduce Enteric Methane Emissions by 80%
    Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults
    Nexira to Discuss Four New Scientific Studies at Vitafoods Europe Nexira to Discuss Four New Scientific Studies at Vitafoods Europe
    FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products
    Arjuna will Feature New Study on Sports Nutrition Ingredient at Vitafoods Europe Arjuna will Feature New Study on Sports Nutrition Ingredient at Vitafoods Europe
    IFF to Discuss Customizable, Sustainable Solutions for Supplements IFF to Discuss Customizable, Sustainable Solutions for Supplements
    AB-Biotics to Bring Latest Probiotic Solutions at Vitafoods Europe AB-Biotics to Bring Latest Probiotic Solutions at Vitafoods Europe
    Nutraceuticals for Men: Muscle Health and Performance Nutrition Nutraceuticals for Men: Muscle Health and Performance Nutrition
    Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing
    Aging in Place: Healthy Lifestyles Supplement Science-Based Solutions Aging in Place: Healthy Lifestyles Supplement Science-Based Solutions
    Indena’s Meriva Curcumin Supplement May Benefit Kidney Function Indena’s Meriva Curcumin Supplement May Benefit Kidney Function
    Undenatured Type II Collagen Ingredient Backed by Study for Joint Health Benefits Undenatured Type II Collagen Ingredient Backed by Study for Joint Health Benefits
    Market Shifts in Joint and Muscle Health Market Shifts in Joint and Muscle Health

    Related Content

    • Dietary Supplements | Healthy Aging | Regulations | World Markets
      Experts Debate Role of Supplements in Improving Public Health in EU

      Experts Debate Role of Supplements in Improving Public Health in EU

      At a panel discussion supported by Food Supplements Europe, stakeholders discussed regulation, bridging nutrient gaps, nutrition literacy, and more.
      By Mike Montemarano, Associate Editor 05.16.22

    • Breaking News | Dietary Supplements | Industry & Market News | Quality & Safety | Testing
      Quality Testing of CoQ10 and Quercetin Brands Sold on Amazon Finds Continued Failure

      Quality Testing of CoQ10 and Quercetin Brands Sold on Amazon Finds Continued Failure

      Potency issues are prevalent, and several brands claiming to offer products in vegetarian capsules were found to contain gelatin.
      05.10.22

    • Breaking News | Energy | Industry & Market News | Marine Nutraceuticals | World Markets
      Red Seaweed Digestive Supplement for Cattle Could Reduce Enteric Methane Emissions by 80%

      Red Seaweed Digestive Supplement for Cattle Could Reduce Enteric Methane Emissions by 80%

      Blue Ocean Barns’ product Brominata has been approved for sale in California.
      05.10.22


    • Cancer Risk | Omega-3s | Research | Vitamins
      Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults

      Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults

      A three-year, multicenter trial known as DO-HEALTH tracked 2,157 older adults who took vitamin D and/or omega-3s both with and without exercise.
      By Mike Montemarano, Associate Editor 05.06.22

    • Nexira to Discuss Four New Scientific Studies at Vitafoods Europe

      Nexira to Discuss Four New Scientific Studies at Vitafoods Europe

      Each study was conducted on a different ingredient from the company’s portfolio.
      05.05.22

      Trending
      • Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk In Older Adults | Nutraceuticals World
      • Indena’s Meriva Curcumin Supplement May Benefit Kidney Function
      • Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults
      • Test On Hydrolyzed Collagen Shows Resoundingly High Bioavailability | Nutraceuticals World
      • Vitamin K2 Status May Impact Blood Pressure And Pulse Wave Velocity | Nutraceuticals World
      Breaking News
      • Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan
      • Solvay Invests in Suanfarma’s Vanillin Production
      • GNC Adds Products from The Honest Company, Hers, and Womaness
      • NSF and SCNM’s School of Nutrition Collaborate on Master of Science Program
      • Walgreen’s Brand Vitamins and Supplements First to Carry UL Verified Mark
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Aging in Place: Lifestyle Supplements Science-Based Solutions
      • Getting an Edge in Esports: Meeting Health & Nutrition Needs
      • Nutraceuticals for Men: Muscle Health and Performance Nutrition

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan
      Solvay Invests in Suanfarma’s Vanillin Production
      GNC Adds Products from The Honest Company, Hers, and Womaness
      Coatings World

      Latest Breaking News From Coatings World

      PPG Launches HOMAX TEX>>PRO Texture System by PPG
      New Digital Solution from Interpon Helps Customers Bring Colors to Life
      What Are You Reading?
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Texas Medical Center Partners with Enterprise Ireland
      MMT Acquires Medical Production Technology Europe
      Avanos Recalls Cortrak*2 Over Potential Enteral Tube Misplacement
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Catalent Introduces UpTempo Virtuoso Platform
      Elicio Therapeutics Enters Clinical Supply Agreement with Regeneron
      Reaction Biology Expands Executive Leadership Team
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      A Look at Machine Gun Kelly's $30K Diamond Mani
      Doja Cat Rocks Glam Makeup & Nails at the Billboard Music Awards
      Maggie Q Launches Beauty Supplement
      Happi

      Latest Breaking News From Happi

      Dr. Squatch Launches Black Hole Bar Soap in Light of Recently-Revealed Black Hole in Milky Way
      Nautica Introduces Nautica Oceans Pacific Coast Collection
      Thread Beauty Launches Vegan Lip Gloss Collection
      Ink World

      Latest Breaking News From Ink World

      INX to Highlight Color Perfection Program, INX University at GulfCan
      Kornit Hosts Kornit Fashion Week London 2022
      Zeller+Gmelin Launches UV-Curable and Water-Based Inkjet Inks
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Schreiner ProTech introduces new PCS solution for electric vehicle charging
      FTA and FFTA announce 2022-2023 board updates
      Bar Graphic and J&J Converting open US demo center
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Essity Wins Innovation Award at Interclean
      Weekly Recap: Ontex Confirms Possibility of Attindas Deal, Purell Launches New Wipes & More
      TSG Finishing Starts Modernization Project
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Denise Pedulla Appointed as Chief Legal Officer at Conformis
      ODT's Most-Read Stories This Week—May 14
      Steven Haddad Joins Extremity Medical as Chief Clinical Officer
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Tageos Highlights New RFID Products at RFID Journal Live! 2022
      LG Display’s Research Results Reaffirm OLED is Optimal Gaming Display
      Google Cloud, Saule Technologies and Columbus Energy Begin Strategic Cooperation

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login